RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13
RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and raises the price target from $12 to $13.
Read original at benzingaStocks · News reference
Ardent Health Partners Q2 EPS $0.12 Misses $0.19 Estimate, Sales $1.622B Beat $1.590B Estimate
Ardent Health Partners (NYSE:ARDT) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.19 by 36.84 percent. This is a 76.92 percent decrease over earnings of $0.52 per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 8:16 PM
- Checked
- Aug 4, 2026, 8:16 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Truist Securities Maintains Buy on Ardent Health, Raises Price Target to $13
Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $12 to $13.
Read original at benzingaGuggenheim Maintains Buy on Ardent Health, Raises Price Target to $14
Guggenheim analyst Jason Cassorla maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $13 to $14.
Read original at benzingaArdent Health shares are trading higher after the company reported better-than-expected Q2 sales results and affirmed its FY26 sales guidance with its midpoint above estimates.
Read original at benzinga